Aragon finds investor with 'deep pockets' in $42m round for cancer combo development
This article was originally published in Scrip
With the help of a new investor and $42 million in fresh capital, San Diego-based Aragon Pharmaceuticals can continue Phase II studies for its castration-resistant prostate cancer drug ARN-509 without a pharmaceutical partner and advance its preclinical breast cancer compound.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.